Oragenics, Inc. OGEN
0.35 USD -0.02 (-6.18%)
At closeNov 5, 2026, 4:00 PM EST
0.39 +0.04 +11.00%
After hours · Nov 5, 4:00 PM ET
0.3441 Day range 0.3622
0.3441 52-week range 1.22
- YTD
- -55.26%
- 1 year
- -69.39%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
globenewswire.com Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the…
benzinga.com Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its…
globenewswire.com Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary…
defenseworld.net Oragenics (NYSEAMERICAN:OGEN) Trading Up 0.2% – Time to Buy? Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) traded up 0.2% on Tuesday. The stock traded as high as $0.5490 and last traded at $0.5489. 31,024 shares changed hands during mid-day…
globenewswire.com Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital…
globenewswire.com Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics,…
globenewswire.com ORAGENICS PROVIDES INVESTOR UPDATE A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has…
benzinga.com Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY Oragenics (AMEX:OGEN) reported quarterly losses of $(0.51) per share. This is a 85.83 percent increase over losses of $(3.60) per share from the same period last year.- benzinga.com Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain BarrierSarasota, FL and San…
globenewswire.com Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and…
globenewswire.com Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal…
benzinga.com Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury • Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stagesSARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a…
globenewswire.com Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury • Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla. , April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:…- benzinga.com Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002 Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need
globenewswire.com Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal…
defenseworld.net Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Rises By 39.0% Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling…
globenewswire.com Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal…- benzinga.com Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has…
globenewswire.com ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering…
benzinga.com Oragenics Explores Acquisition Of Additional Assets In Central Nervous System Space; No Definitive Agreements Signed Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is…
globenewswire.com ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal…- benzinga.com Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has…
globenewswire.com Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites Potential first and only pharmacological treatment for the most prominent…
defenseworld.net Oragenics (NYSEAMERICAN:OGEN) Trading Down 0.3% – Here’s Why Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) fell 0.3% during mid-day trading on Tuesday. The company traded as low as $0.7839 and last traded at $0.8295. 74,417 shares traded…
benzinga.com Oragenics Previews 2026 Milestones; Outlines Clinical And Growth Catalysts For ONP-002 In Concussion And mTBI Oragenics, Inc. (NYSE:OGEN) ("the "Company") a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today previewed its…
globenewswire.com Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in…
benzinga.com Oragenics Engages DUCK FLATS Pharma As It U.S. Investigational New Drug Readiness, Regulatory Execution Partner To Support FDA-Facing Preparation, Clinical Study Design Oragenics, Inc. (NYSE American: OGEN) ("the "Company"), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced it has engaged…
globenewswire.com Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket 
benzinga.com Reported November 7, 2025: Oragenics Q3 EPS $(1.96) Up From $(11.32) YoY Oragenics (AMEX:OGEN) reported quarterly losses of $(1.96) per share. This is a 82.69 percent increase over losses of $(11.32) per share from the same period last year.- benzinga.com Oragenics Regains Nasdaq Compliance Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has…
- benzinga.com Oragenics Selects Southern Star Research As Clinical Research Organization For Upcoming Phase IIa Clinical Trial Of ONP-002, Lead Drug Candidate For Concussion Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its…
- benzinga.com Oragenics Enters Manufacturing Agreement With Sterling Pharma For GMP Production Of Concussion Drug, ONP-002 Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June 
benzinga.com US Stocks Mixed; Dow Gains Over 50 Points - benzinga.com Oragenics Prices Public Offering Of Up To $20M Of Preferred Stock And Warrants Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Oragenics Receives Approval From HREC In Australia To Initiate Phase II Clinical Trial Evaluating ONP-002 For Treatment Of mTBI Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session